Labeling & Imaging
For nuclear imaging in preclinical and clinical research, your drug needs to be radiolabeled with a radionuclide suitable for PET or SPECT. For therapeutic radiopharmaceuticals, a surrogate radionuclide may sometimes be needed.
We offer labeling services with various radionuclides and chelators, enabling imaging studies for many types of compounds and biologics. Lastly, the chosen radionuclide needs to be matched with the imaging equipment available at the clinical sites where your trial will be conducted. As a CRO, we assist you in the complete process.
Imaging modalities
|
Functional radiology |
Structural radiology |
Optical Imaging |
Others |
|
PET (including whole/total body) |
MRI |
Fluorescence endoscopy |
Raster-Scan Optoacoustic Mesoscopy (RSOM) |
|
PET/CT |
CT |
In vivo and ex vivo fluorescence |
Autoradiography (ex vivo with radioactivity) |
|
SPECT |
X-ray |
Optoacoustic imaging |
Quantitative fluorescence spectroscopy |
|
SPECT/CT |
Fluoroscopy |
Ultrasound |
Raman spectroscopy (non-labeling technique) |
(Radio)labels for imaging
- All common fluorescent labeling
- Radiolabeling with most common radioisotopes:
|
Zirconium-89 |
Iodine-124 |
Iodine-123 |
Technetium-99m |
|
Fluorine-18 |
Lead-203 |
Copper-64 |
Indium-111 |
|
Carbon-11 |
Gallium-68 |
And others |
|
Other radioisotopes available upon request.
Therapeutic radionuclides
- All common alpha- and beta-emitting radionuclides
|
Actinium-225 |
Lead-212 |
Astatine-211 |
Terbium-161 |
|
Iodine-131 |
Lutetium-177 |
And others |
